It’s in the Genes: Top 5 Things to Know about Genetic Testing (07-8-2016)

Advances in genetic testing are offering women more information than ever before about their genetic makeup and are providing opportunities for empowered decision-making related to a wide range of health issues. In this recurring column, experts provide... Continue Reading

Darzalex™ Effective in Heavily Pre-Treated Multiple Myeloma (07-7-2016)

The targeted agent Darzalex (daratumumab) produces long-lasting anti-cancer responses among patients with multiple myeloma that has stopped responding to several prior therapies. These results were recently published in the journal Blood. Multiple myeloma... Continue Reading

Blincyto® Improves Survival in Type of Acute Lymphoblastic Leukemia (06-23-2016)

The immunotherapeutic agent, Blincyto (blinatumomab), improves survival compared to standard therapy among patients with B-cell precursor, Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (BCP-ALL) that has stopped responding to prior... Continue Reading

Lenvima® Approved for Kidney Cancer (05-24-2016)

The United States Food and Drug Administration (FDA) has approved Lenvima® (lenvatinib) for the treatment of kidney cancer. The approval is for patients with advanced renal cell carcinoma who have received at least one prior therapy with an anti-angiogenic... Continue Reading

Shorter Radiation Schedule Effective in Low-Risk Prostate Cancer (03-9-2016)

Men with low-grade prostate cancer have the same long-term outcomes when they are treated with a shorter radiation schedule, compared to those treated with a longer, conventional radiation schedule. These results were recently presented at the 2016 annual... Continue Reading

Empty Feed (11-6-2015)

 Read More →

Empty Feed (11-5-2015)

 Read More →

Empty Feed (11-4-2015)

 Read More →

Empty Feed (11-3-2015)

 Read More →

Empty Feed (11-2-2015)

 Read More →

Next Page »